Sindrom pelepasan sitokin

Sindrom pelepasan sitokin (CRS)
Sindrom pelepasan sitokin (CRS)
Informasi umum
Nama lain	Reaksi terkait infusi, reaksi infusi, badai sitokin
Spesialisasi	Imunologi

Sindrom pelepasan sitokin (bahasa Inggris: cytokine release syndrome, disingkat CRS) atau sindrom badai sitokin (cytokine storm syndrome, disingkat CSS) adalah salah satu bentuk sindrom respons inflamasi sistemik (SIRS) yang dapat dipicu oleh berbagai faktor seperti infeksi dan obat-obatan tertentu.^[3] Kondisi ini terjadi ketika sejumlah besar sel darah putih teraktivasi dan melepaskan sitokin radang, yang pada gilirannya mengaktifkan lebih banyak lagi sel darah putih. CRS juga merupakan efek samping dari beberapa obat antibodi monoklonal, serta terapi sel T adoptif.^[4]^[5] Kasus yang berat disebut badai sitokin.^[2] Ketika terjadi sebagai akibat dari pemberian obat, kondisi tersebut juga dikenal sebagai reaksi infusi.^[1]

Referensi

^ ^a ^b Vogel WH (April 2010). "Infusion reactions: diagnosis, assessment, and management". Clinical Journal of Oncology Nursing. 14 (2): E10–21. doi:10.1188/10.CJON.E10-E21. PMID 20350882.
^ ^a ^b Vidal JM, Kawabata TT, Thorpe R, Silva-Lima B, Cederbrant K, Poole S, Mueller-Berghaus J, Pallardy M, Van der Laan JW (August 2010). "In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop". Cytokine. 51 (2): 213–15. doi:10.1016/j.cyto.2010.04.008. PMID 20471854.
^ Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. (15 June 2018). "Cytokine release syndrome". J Immunotherapy Cancer. 6 (1): 56. doi:10.1186/s40425-018-0343-9. PMC 6003181 . PMID 29907163.
^ Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL (July 2014). "Current concepts in the diagnosis and management of cytokine release syndrome". Blood. 124 (2): 188–95. doi:10.1182/blood-2014-05-552729. PMC 4093680 . PMID 24876563.
^ Kroschinsky F, Stölzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P (April 2017). "New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management". Critical Care. 21 (1): 89. doi:10.1186/s13054-017-1678-1. PMC 5391608 . PMID 28407743.

[Vog2010-1] Vogel WH (April 2010). "Infusion reactions: diagnosis, assessment, and management". Clinical Journal of Oncology Nursing. 14 (2): E10–21. doi:10.1188/10.CJON.E10-E21. PMID 20350882.

[EMAws2010-2] Vidal JM, Kawabata TT, Thorpe R, Silva-Lima B, Cederbrant K, Poole S, Mueller-Berghaus J, Pallardy M, Van der Laan JW (August 2010). "In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop". Cytokine. 51 (2): 213–15. doi:10.1016/j.cyto.2010.04.008. PMID 20471854.

[3] Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. (15 June 2018). "Cytokine release syndrome". J Immunotherapy Cancer. 6 (1): 56. doi:10.1186/s40425-018-0343-9. PMC 6003181 . PMID 29907163.

[Blood2014-4] Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL (July 2014). "Current concepts in the diagnosis and management of cytokine release syndrome". Blood. 124 (2): 188–95. doi:10.1182/blood-2014-05-552729. PMC 4093680 . PMID 24876563.

[Kroschinsky2017rev-5] Kroschinsky F, Stölzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P (April 2017). "New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management". Critical Care. 21 (1): 89. doi:10.1186/s13054-017-1678-1. PMC 5391608 . PMID 28407743.

[1]

[2]

[3]

[4]

[5]